DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
暂无分享,去创建一个
S. Lonial | S. Trudel | P. Richardson | N. Callander | A. Nooka | T. Facon | A. Chari | J. Opalinska | A. Cohen | E. Libby | I. Gupta | Hans C. Lee | S. Paul | B. Besemer